Tag: Cancer Prevention and Screening
[News] Largest trial of AI in breast cancer screening launched
The UK’s National Health Service (NHS) has launched the world’s largest prospective trial of using artificial intelligence (AI) to assess routine mammogram screenings. Nearly 700 000 women who have booked routine screenings in the UK will be invited to participate from April, 2025.
Making Biliary Tract Cancer Treatment More Precise
Tumors arising in the gallbladder, bile ducts, and the small intestine are collectively referred to as biliary tract cancers. These cancers are rare—affecting approximately 12,350 individuals in 2024—but they are typically diagnosed at advanced stages when surgery, which can improve prognosis, is no longer an option. Angela Lamarca, MD, PhD Systemic therapies, therefore, are the… Continue reading Making Biliary Tract Cancer Treatment More Precise
Less-frequent surveillance is noninferior to annual mammography
Most women with newly diagnosed breast cancer remain alive and recurrence-free for many years after complete surgical resection. Thus, whether all these women require annual follow-up mammography remains uncertain. Now, data from the phase III Mammo-50 trial demonstrate that most women can safely undergo follow-up mammography at 2-yearly or 3-yearly intervals. A total of 5,235 women… Continue reading Less-frequent surveillance is noninferior to annual mammography
Genetic variations and carcinogenicity analysis of E6/E7 oncogenes in HPV31 and HPV35 in Taizhou, China
The purpose of this study was to investigate the genetic variations in the E6 and E7 oncogenes of HPV31 and HPV35, and to explore their potential role in cervical cancer risk among women in Taizhou, China. Continue reading on BioMed Central
Estimating cancer incidence attributable to physical inactivity in the United States
Abstract Background Previous estimates of the number of cancers attributable to physical inactivity in the United States have typically focused on only three malignancies (colon, endometrial, and postmenopausal breast cancer). Contemporary epidemiologic evidence suggests that physical inactivity could contribute to up to 15 types of cancer, and a dose–response effect has been demonstrated for 13… Continue reading Estimating cancer incidence attributable to physical inactivity in the United States
Estimating cancer incidence attributable to physical inactivity in the United States
Abstract Background Previous estimates of the number of cancers attributable to physical inactivity in the United States have typically focused on only three malignancies (colon, endometrial, and postmenopausal breast cancer). Contemporary epidemiologic evidence suggests that physical inactivity could contribute to up to 15 types of cancer, and a dose–response effect has been demonstrated for 13… Continue reading Estimating cancer incidence attributable to physical inactivity in the United States
A phase 1 dose‐escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma
This phase 1 study demonstrated that LY3295668 erbumine, a highly selective, orally bioavailable, and reversible Aurora kinase A inhibitor, both as monotherapy and in combination with standard chemotherapy in children with relapsed/refractory neuroblastoma, had a manageable safety profile. Despite robust preclinical data, relatively modest clinical activity (two partial responses and two minor responses with combination… Continue reading A phase 1 dose‐escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma
A phase 1 dose‐escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma
This phase 1 study demonstrated that LY3295668 erbumine, a highly selective, orally bioavailable, and reversible Aurora kinase A inhibitor, both as monotherapy and in combination with standard chemotherapy in children with relapsed/refractory neuroblastoma, had a manageable safety profile. Despite robust preclinical data, relatively modest clinical activity (two partial responses and two minor responses with combination… Continue reading A phase 1 dose‐escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma
New biomarker test detects early tau tangles in Alzheimer’s disease
Years before tau tangles show up in brain scans of patients with Alzheimer’s disease, a biomarker test developed at the University of Pittsburgh School of Medicine can detect small amounts of the clumping-prone tau protein and its misfolded pathological forms that litter the brain, cerebrospinal fluid and potentially blood, new research published today in Nature… Continue reading New biomarker test detects early tau tangles in Alzheimer’s disease